Aetos Wins Coveted R&D 100 Award for CytoViva™ Technology
Complete the form below to unlock access to ALL audio articles.
Aetos Technologies, Inc has announced that CytoViva™ has been selected by R&D Magazine as one of the top 100 most technologically significant products introduced to the marketplace in 2006.
This prestigious international award is often referred to as the 'Oscar of Inventions.'
Invented at Auburn University and commercialized by Aetos Technologies, Inc., CytoViva™ is a product combining fluorescence and high resolution optical imaging to create an unparalleled level of microscopy performance.
This system is designed to allow researchers to view both fluorescent and non-fluorescent sample structures simultaneously, in real-time and at high resolution.
To date, the CytoViva™ system has been used by scientists representing laboratories in academic, government and private industry sectors.
Research in these laboratories include initiatives focused on infectious disease, nanotechnology and drug discovery.
For example, CytoViva enables observation of the toxic effect of nano-particles used for targeted drug delivery.
Charles T. Ludwig, President of the company's CytoViva™ division notes, "In its first year of commercialization, applications for CytoViva have already extended beyond traditional biological research to include materials science based researchers, many of whom are on the forefront of the nanotechnology revolution."
"We are honored to receive this award as it further validates what our scientific customers have already told us about CytoViva's ability to impact their research efforts."
Aetos will be recognized in the September edition of R & D Magazine and at the 44th annual banquet held in Chicago, where the magazine is based.
Aetos' Chairman and CEO, Thomas R. Lawrence, said, "This award once again demonstrates that our universities have technologies that have commercial viability."
"Having a mechanism such as Aetos Technologies to move research from laboratory to market plays a critical role in commercial success stories."